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Pegylated interferon alpha-2a for essential 
thrombocythemia during pregnancy: outcome and
safety. A case series
Pregnant woman with essential thrombocythemia (ET)
are at higher than normal risk of pregnancy complica-
tions. Current recommendations suggest that aspirin and
cytoreductive therapy should be offered for high-risk
pregnancies but Pegylated interferon alpha-2a (PEG-IFN)
has never been investigated in this context. From our case
series, including 10 pregnancies, we demonstrate that
PEG-IFN has been well-tolerated, allows reduction and
control of platelet count during pregnancy, and is associ-
ated with a high live birth rate (90%) and low miscarriage
rate (10%).
Essential thrombocythemia (ET), a myeloproliferative
neoplasm, is a rare disease with an estimated incidence of
0.38-1.7/100,000 per year.1 Peak incidence is during the
sixth decade; however, up to 20% of patients are diag-
nosed before the age of 40 years.2 The main risks associ-
ated with ET are thrombosis and hemorrhage, the respec-
tive prevalence of which in young women is 18% and
26%.3 Patients older than 60 years and/or with previous
history of thrombosis and /or with platelet count greater
than 1500x109/L are considered to be at high risk of
thrombotic events and cytoreductive treatment is gener-
ally recommended4 as a consequence. Previous descrip-
tive studies of pregnancy in women with ET suggested a
risk of first trimester miscarriage of 27% with a live birth
rate of only 64%.5 Data currently available on pregnancy
outcome in ET are based on retrospective cohorts, and
the impact of variables including presence of JAK2V617F,
prior pregnancy complications, therapy, high leukocyte
count and platelet count are contradictory  A recent study
showed a trend towards better outcome for patients har-
boring CALR mutations.7 The benefit of low-dose aspirin
(ASA) is contradictory, with some studies suggesting a
reduction of miscarriage in treated patients6 and others
not.8 However, safety of ASA in this population is well
established.9 Currently, interferon alpha (IFN) and PEG-
IFN are not approved for ET and pregnancies and should
be used in pregnancy only if benefits justify the potential
risk to the fetus (category C). However, one retrospective
study reported safety for IFN-treated pregnant patients
with an increase in live birth rate,8 and current recom-
mendations consider IFN as a reasonable treatment.4
There are currently no data relating the safety and effica-
cy of PEG-IFN in pregnant ET patients. Only one case of
pregnant ET10 and anecdotal use of PEG-IFN in different
pregnancy scenarios (CML, hepatitis) have previously
been reported. For this reason, PEG-IFN is currently not
recommended for pregnant ET patients.
In this observational study, we included pregnant
women with a diagnosis of ET treated with PEG-IFN
with pregnancy outcome available. Patients were identi-
fied by physicians who agreed  to participate in the study.
Five centers in the UK (Guy's and St. Thomas' NHS
Foundation Trust, London; St James's University
Hospital, Leeds; University Hospital of Wales, Cardiff;
Beatson West of Scotland Cancer Centre, Glasgow;
Countess of Chester Hospital, Chester) participated in
this study. PEG-IFN was used off label and initiation of
other drugs (e.g. ASA, LMWH) reflects the choice of the
treating physician. Demographics, past medical and
obstetric history, previous thrombosis and hemorrhage,
previous treatment, disease characteristics at diagnosis
and during pregnancy were retrospectively extracted
from patients’ notes. This study was performed in accor-
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Table 1. Patients' characteristics; n=10 pregnancies in 8 women.
Pt. Age at PLT Obstetric Thrombosis Age at Pregnancy Gestation Birth- Maximum Concomitant Median Median Median
n. diagnosis count at history* history conception outcome at pregnancy weight PEG-IFN dose treatment PLT count PLT count PLT count
diagnosis (years), outcome during during during during during
on PEG-IFN (weeks+days) pregnancy pregnancy first second third
trimester trimester trimester
(x109/L) (x109/L) (x109/L)
1 34 791 1 LB None 39 LB 40+0 3.1 90 µg ASA, 346 306 262
e1w LMWH pd
2 33 702 1 LB, 3 MC Sagittal 39 LB 39+1 3.1 135 µg ASA, 254 225 183
thrombosis e5w LMWH td
3 22 1600 None None 24 MC 6+0 NAp 45 µg e1w ASA 512 NAp NAp
3 22 1600 1 MC None 25 LB 38+3 4.1 45 µg e1w ASA 434 435 370
4 18 2000 1 MC None 24 LB 40+6 3.7 45 µg e1w ASA, 265 N/A 333
LMWH pd
5 12 3265 1 TOP None 21 LB 38+4 2.8 270 µg e1w ASA 570 454 428
6 23 1693 1MC None 33 LB 39 3.1 90 µg e1w ASA, 446 469 350
LMWH pd
6 23 1693 1LB, 1MC None 36 LB 42 3.2 90 µg e1w ASA, 442 393 288
LMWH pd
7 30 664 1 LB Portal vein 34 LB 39 2.5 45 µg e2w LMWH td 223 220 217
thrombosis
8 23 960 None None 31 LB 40 3.1 135 µg e1w ASA 612 473 467
Pt: patient; ASA: aspirin; e1w: every 1 week; e2w: every 2 weeks; e5w: every 5 weeks; LB: live born; LMWH: low-molecular weight heparin; MC: miscarriage; N/A: not available; NAp: not
applicable; PLT: platelet; pd: prophylactic dose; td: therapeutic dose; TOP: termination of pregnancy. *Obstetric history included all outcomes of prior pregnancies. Patients 3 and 6 had 2 preg-
nancies on PEG-IFN. Therefore, obstetric history is different between the two pregnancies: the obstetrical history of the second pregnancies includes outcome of the first one.
dance with the Declaration of Helsinki. Patients' charac-
teristics were reported descriptively. Categorical variables
were expressed as proportions and continuous variables
as the median with the range. Nominal variables were
compared with Fisher's test. Comparison of dependant
variables were analysed by Friedman test. Two-sided 
P<0.05 was considered significant. Objectives were to
describe pregnancy outcomes including live birth, fetal
loss, birthweight, mode of delivery, gestation at delivery;
efficacy (platelet count during pregnancy) and tolerability
of PEG-IFN during pregnancy.
The study included 10 pregnancies in 8 women
observed between 2013 and 2015. In all cases, the diag-
nosis of ET had been made prior to pregnancy. Median
age and median platelet count at diagnosis were 23 years
(range 12-34 years) and 1280x109/L (range 664-
3265x109/L), respectively. At diagnosis, 6 (75%) patients
were considered high risk (4 with platelet count
>1500x109/L and 2 with history of thrombosis: 1 sagittal
vein thrombosis and 1 portal vein thrombosis). Five
(63%) were JAK2V617F positive. Comprehensive details
of mutational status were not available for the remaining
patients. Six women (75%) had a prior documented his-
tory of 9 pregnancies without PEG-IFN with 3 (33%) live
births, 5 miscarriages (56%) and one voluntary termina-
tion of pregnancy (11%). During the 5 pregnancies that
resulted in miscarriages, all women were on ASA, one on
low molecular weight heparin (LMWH), and one on IFN.
Of the 3 previous live births, one mother received ASA
alone and experienced neurological symptoms with right
hemi-facial and upper limb numbness during pregnancy,
and the neonate was of low birth weight and placental
histology suggesting insufficiency; one was on IFN, and
therapeutic dose LMWH following prior thrombosis
complications included a placental hemorrhage and per-
ineal hematoma; and one was on ASA and prophylactic
dose of LMWH (delivered without any complication).
Median age during pregnancy with PEG-IFN was 32
years (range 21-39 years). PEG-IFN was started before
conception in all women. In addition to PEG-IFN, all but
one woman (the case with previous portal vein thrombo-
sis on long-term anticoagulation) were on ASA and 5
(63%) of them were on LMWH [3 (38%) on prophylactic
dose and 2 (25%) on therapeutic dose for previous
thrombosis]. The rationale for the introduction of cytore-
ductive treatment was high-risk ET for 6 women (75%),
ET-related symptoms in one (13%), and complications in
previous pregnancy in one woman (13%). Median dose
of PEG-IFN was 270 mcg/month (range 90-1080
mcg/month). Five woman experienced PEG-IFN grade 1
adverse events (AEs) (2 reported hair loss, one had mild
mood swing, one had fatigue, one had transient nausea,
anorexia and abdominal pain, one had a skin reaction,
one had headaches) and one had grade 2 AEs (neutrope-
nia). Neither grade 3-4 AEs nor drug discontinuation was
reported. There was a significant reduction in the platelet
count during pregnancies managed with PEG-IFN
(P<0.05). Median platelet count at conception 
was 509x109/L (354-676x109/L), 438x109/L (range 223-
612x109/L) during the first trimester, 414x109/L (range
220-473x109/L) during the second trimester, 333x109/L
(range 183-467x109/L) during the third trimester and
285x109/L (range 172-460x109/L) at delivery.
Of the 10 pregnancies, all were singleton. Nine (90%)
resulted in live birth and one (10%) in miscarriage (at 7
weeks, platelet count 492x109/L). Median time of gesta-
tion at delivery was 39 weeks (range 38+3-42 weeks) and
median birthweight was 3.1 kg (range 2.5-4.1 kg). Delivery
was vaginal for 8 (89%) and by caesarean section for one
(11%) (breech presentation), with induction of labor for 2
(22%). Neither major bleeding nor thrombosis were
reported during pregnancy, delivery or post-partum. There
were neither stillbirths nor infant malformations. Finally,
when comparing outcomes of pregnancies of these 8
women on PEG-IFN or without (after having excluded 1
voluntary termination of pregnancy from the analysis),
there were significantly more live births on PEG-IFN (9 vs.
3; P<0.05) and fewer miscarriages (1 vs. 5; P<0.05).
Confounding factors such as LMWH use for outcome was
also investigated. Even if we demonstrated a trend
towards a better outcome using LMWH for pregnancies
prior PEG-IFN (live birth 2/3 on LMWH; miscarriage 1/5
on LMWH; P=0.464) or for all pregnancies (live birth: 8/12
on LMWH; miscarriage 2/6 on LMWH; P=0.321) it did not
reach significance. The principal patients’ characteristics
and outcomes are summarized in Table 1.
This observational study (including 10 pregnancies in 8
ET patients) is the first case series of pregnant women
treated with PEG-IFN evaluating pregnancy outcome, tol-
erance and safety. Here the rate of fetal loss (10%) is less
than previously reported in retrospective cohort studies
(34.5%-39.7%)  and is in accordance with the reported
outcomes of women treated with IFN during pregnancy.8
Moreover we did not report any maternal, fetal compli-
cations or malformations. In terms of hematologic effica-
cy, platelet counts were well controlled with PEG-IFN,
during pregnancy. PEG-IFN was relatively well tolerated
and only a few grade 1-2 AEs were reported. No women
experienced grade 3-4 side-effects or discontinued PEG-
IFN due to toxicity. In past studies, standard IFN was
shown to control platelet count in ET patients but was
associated with significant and frequent side-effects caus-
ing drug discontinuation in up to 66%.14 Moreover,
because of its short half-life, patients usually required
several subcutaneous injections per week. The efficacy of
PEG-IFN in controlling the platelet count is similar to IFN,
but its longer half-life allows less frequent injections and
its tolerance profile results in less drug withdrawal.15-17
The main limitation of our study was the small number
of pregnancies reported; a key strength was that the man-
agement of these pregnancies is homogeneous and in
accordance with modern obstetric and hematology prac-
tice, and more likely to reflect real time outcome data. 
In addition, we cannot exclude the possibility  that
other confounding factors (e.g. LMWH use), in addition
to PEG-IFN, contribute to the improvement in pregnancy
outcomes. Although it would be naïve to suggest these
data fully confirm the safety and efficacy of PEG-IFN,
these provisional results do support ongoing use of PEG-
IFN in the absence of evidence of harm and provide an
alternative better tolerated treatment. Case ascertain-
ment was based upon the physician's willingness to par-
ticipate, and inclusion bias cannot be excluded. However,
to avoid this bias, we requested that contributing hema-
tologists included all pregnancies in women with a diag-
nosis of ET who received PEG-IFN, regardless of efficacy,
complications or side-effects.
Current guidelines recommend using IFN as first-line
for high-risk pregnant patients.4Our results highlight effi-
cacy, safety and good tolerance of PEG-IFN, which could
be an effective and safe alternative to IFN for pregnant
woman with ET requiring cytoreduction. 
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